Phase
Condition
Heart Failure
Chest Pain
Hyponatremia
Treatment
Sacubitril-Valsartan
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Symptomatic heart failure (NYHA functional class II to IV)
Reduced LV ejection fraction (≤ 40%)
Clinical indication for therapy with Sacubitril-Valsartan
Exclusion
Exclusion Criteria:
catecholamine therapy at inclusion
existing therapy with Sacubitril-Valsartan
planned cardiac resynchronization therapy (CRT) within 6 months; inclusion at least 3 months after CRT
planned mitral or aortic valve procedure within 6 months; inclusion at least 3months after valve procedure
participation in another randomized heart failure trial
severe aortic or mitral valve lesion
Study Design
Connect with a study center
University of Leipzig
Leipzig, Saxony 04103
GermanySite Not Available
Kardiopraxis Schirmer
Kaiserslautern,
GermanySite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.